2016 CONFERENCE
Saving Lives: Access to Improved Health & Recovery

OCTOBER 29–NOVEMBER 2, 2016

Baltimore Marriott Waterfront
Baltimore, Maryland

REGISTER BY:
SEPTEMBER 30, 2016
TO TAKE ADVANTAGE OF PRE-REGISTRATION DISCOUNT

aatod.org
FROM THE CONFERENCE CHAIR

Dear Friends and Colleagues,

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), it gives me great pleasure to invite you to the 2016 AATOD Conference being held October 29 to November 2, 2016 at the Marriott Waterfront Hotel in Baltimore, Maryland. The 2016 Conference is sponsored by the Maryland Behavioral Health Administration in conjunction with the Opioid Treatment Providers of Maryland.

AATOD has a long history of providing an outstanding conference which has consistently provided conference attendees with new and exciting avenues for learning and networking. And 2016 will be no different. During this conference Maryland providers have put together an outstanding workshop filled with art and healing titled, *The New Day Campaign: Where Stigma Ends, Healing Begins*. The workshop will highlight poetry, music, painting, and other art forms focused on the intersection of art and healing as a way to help end the stigma so often associated with substance use disorders. This will be an experience you won’t want to miss.

The conference will be filled with many opportunities to network with others working in the Medication Assisted Treatment (MAT) field and to gain knowledge about meeting the needs of those with co-occurring disorders, opioid overdose prevention, treatment for youth and pregnant women, and many other current issues through workshops and Hot Topic Roundtable Discussions. Presenters from all over the world will be sharing information on how to improve your practice and your treatment program.

The conference theme, “*Saving Lives: Access to Improved Health and Recovery*,” promises to highlight the innovative strategies that are the cornerstone of many behavioral healthcare efforts. Your attendance at the conference will assist you in the development of strategies to improve the collaboration between opioid treatment providers and the systems needed to coordinate care for those we serve so that they can best meet their goals for recovery. Research has proven that effective care coordination increases efficiency and improves clinical outcomes and patient satisfaction with care.

Our plenary speakers have been chosen to assist us in reaching this goal. To name a few, ONDCP Director Michael Botticelli, MEd, SAMHSA/CSAT Director Kimberly Johnson, PhD, and Congressman Elijah Cummings are among the invited plenary speakers. And you won’t want to miss the Clinicians Course, diverse Workshops, timely Hot Topic Roundtables, and numerous vendors available with products and services that will assist your clinic in doing business.

This conference has been designed to meet the needs of everyone from the newbie to the seasoned counselor, administrator, peer recovery advocate, public health professional, and anyone interested in or currently working with medication assisted treatment.

Please plan to join us at the 2016 AATOD conference in Baltimore, Maryland. You won’t be disappointed!

Vickie L. Walters, LCSW-C
2016 Conference Chair
<table>
<thead>
<tr>
<th>Saturday 10-29</th>
<th>7:30 a.m.–5:00 p.m.</th>
<th>Registration Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–5:00 p.m.</td>
<td>The Certified Medication Assisted Treatment Advocate (CMA) Training Course</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.–5:00 p.m.</td>
<td>State Opioid Treatment Authorities Training (Invitation Only)</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.–5:00 p.m.</td>
<td>Developing a Peer Program: An Intensive Hands-on Training for OTP</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Buprenorphine and Office-Based Treatment of Opioid Use Disorders</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Opioid Overdose Prevention and Naloxone Access: Opportunities for Integration into Substance Use Disorder Treatment and Recovery</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Medication Assisted Treatment for Pregnant Women with Opioid Use Disorder—Best Practices and Lessons Learned from Kentucky and Massachusetts</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
<td></td>
</tr>
<tr>
<td>5:00 p.m.–8:30 p.m.</td>
<td>AATOD Open Board Meeting</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sunday 10-30</th>
<th>7:30 a.m.–7:30 p.m.</th>
<th>Registration Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.–5:30 p.m.</td>
<td>State Opioid Treatment Authorities’ Meeting (Closed Session for State and Federal Officials)</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Delivering Integrated Care in the Era of Health Care Reform: Increasing Access to Care Treatment and Services for Improved Outcomes</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Extended Release Naltrexone in Parolees, HIV-Infected Patients and Adolescents/Young Adults with a History of Opioid Use Disorder</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD): EUROPAD Forum</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Partnering to Treat Pregnant Women with Opioid Use Disorders. Lessons Learned from a Six State Initiative</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.–7:30 p.m.</td>
<td>Posters in Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.–7:30 p.m.</td>
<td>Exhibits</td>
<td></td>
</tr>
<tr>
<td>5:30 p.m.–7:30 p.m.</td>
<td>Welcome Reception in Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>7:30 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monday 10-31</th>
<th>7:30 a.m.–5:30 p.m.</th>
<th>Registration Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.–8:45 a.m.</td>
<td>Poster Author Session–Author(s) presentation including Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.–4:30 p.m.</td>
<td>Exhibits (Exhibit Hall closed 9:30 a.m.–11:30 a.m.)</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.–4:30 p.m.</td>
<td>Posters in Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Opening Plenary Session—The Opioid Crisis—Urgent Need for Timely Action</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.–4:30 p.m.</td>
<td>Exhibits</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch (on your own)</td>
<td></td>
</tr>
<tr>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions / Hot Topic Roundtables</td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.–4:00 p.m.</td>
<td>Exhibitor Networking Break in Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.–4:00 p.m.</td>
<td>Poster Author Session–Author(s) presentation including Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.–5:30 p.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>6:30 p.m.–8:30 p.m.</td>
<td>The New Day Campaign: Where Stigma Ends, Healing Begins</td>
<td></td>
</tr>
<tr>
<td>7:00 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tuesday 11-1</th>
<th>7:30 a.m.–3:30 p.m.</th>
<th>Registration Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Exhibits</td>
<td></td>
</tr>
<tr>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Posters in Grand Ballroom</td>
<td></td>
</tr>
<tr>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Middle Plenary Session—Saving Lives: Access to Improved Health &amp; Recovery</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch (on your own)</td>
<td></td>
</tr>
<tr>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.–4:45 p.m.</td>
<td>International Presentations</td>
<td></td>
</tr>
<tr>
<td>7:00 p.m.–9:30 p.m.</td>
<td>Awards Banquet</td>
<td></td>
</tr>
<tr>
<td>9:30 p.m.–10:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wednesday 11-2</th>
<th>7:30 a.m.–1:00 p.m.</th>
<th>Registration Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.–8:00 a.m.</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.–9:30 a.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>9:45 a.m.–11:15 a.m.</td>
<td>Workshop Sessions</td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.–12:45 p.m.</td>
<td>Closing Plenary Session—The Federal Response to the Opioid Epidemic</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.–3:30 p.m.</td>
<td>Clinic Tours (Sign-Up at Hospitality Table)</td>
<td></td>
</tr>
</tbody>
</table>
8:00 a.m.–5:00 p.m.

The Certified Medication Assisted Treatment Advocate (CMA) Training Course

Laura McNicholas, MD, University of Pennsylvania, Philadelphia, PA
Joycelyn Woods, MA, MARS Project, Bronx, NY and NAMA-R, New York, NY
Barry Page, Maryland Department of Health & Mental Hygiene, Catonsville, MD
Cheryl Blankenship Kupras, LCSW, Santa Clara DADS-AMT Program, San Jose, CA and NAMA-R, New York, NY
Zac Talbott, CMA, Counselling Solutions of Chatsworth, Chatsworth, GA and NAMA Recovery, NV/GA Chapter
Brenda Davis, MSW, Beth Israel Medical Center, New York, NY and NAMA-R, New York, NY
Herman Joseph, PhD, Stop Stigma Now, New York, NY and NAMA-R, New York, NY
Center for Substance Abuse and Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

The leading advocate and recovery organization for medication assisted treatment, the National Alliance for Medication Assisted Recovery (NAMA Recovery), developed this training believing that professionals, patients and their families can work together for a better understanding of the physiology of addiction and the use of medication assisted treatment (MAT). Both patients and non-patients are encouraged to become Certified Medication Assisted Treatment Advocates (CMA).

The course presentation includes:

Medication Assisted Treatment—Basic clinical information about methadone and buprenorphine treatment.
Addiction & Methadone—Current science about addiction in a language understandable to the non-clinician.
Regulations & Accreditation—Current regulations explained by the federal agency that oversees methadone and buprenorphine treatment, and the State Opioid Treatment Authority.
Basic Advocacy—Basic tools for advocacy, managing simple issues that confront advocates, educating patients about their rights, handling grievances, legal issues, and working within communities to benefit patients and treatment.

Participants will gain the initial tools for basic advocacy in order to grow and develop into successful advocates. The course involves eight hours of rigorous training and fulfills the training requirement for Certification as a Medication Assisted Treatment Advocate (CMA).

Candidates for certification must register with NAMA Recovery prior to the conference. There is a separate registration fee for the event. The fee includes all materials, 2016/2017 membership in NAMA Recovery, and the application for CMA. Registration information is available at: www.methadone.org. NAMA Recovery cannot guarantee a place to anyone not pre-registered. Lunch is not provided.

Sponsored by the National Alliance for Medication Assisted Recovery (NAMA Recovery)

8:00 a.m. – 5:00 p.m.

Developing a Peer Program: An Intensive Hands-on Training for OTP

Tom Hill, MSW, Senior Advisor, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Walter Ginter, CMA, Director, Medication-assisted Recovery Services (MARS), New York, NY

One-day training to OTP administrators and staff who are interested in developing a peer recovery support services (PRSS) program. Participants will become familiar with both the concepts of peer practice and the nuts and bolts of program planning and implementation. The training will include both didactic presentations and experiential learning exercises, an emphasis on participatory learning, and opportunities for participants to “workshop” ideas. Mr. Hill and Mr. Ginter will equally co-facilitate the presentations, discussion, and exercises.

8:00 a.m.–5:30 p.m.

Buprenorphine and Office-Based Treatment of Opioid Use Disorders

John A. Renner, Jr., MD, Boston University School of Medicine, Education Section VA Outpatient Clinic, Boston, MA
Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Michael Fingerhood, MD, John Hopkins School of Medicine, Baltimore, MD

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid use disorder into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which physicians can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid use disorder. The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid use disorder.

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid use disorder patients by providing: 1) an overview of opioid use disorder, 2) the efficacy and safety of buprenorphine, 3) process of patient selection, 4) clinical use of buprenorphine, 5) nonpharmacological interventions, 6) medical psychiatric conditions in opioid use disorder patients, 7) office procedures, and 8) special treatment population. In total this eight-hour training will include eight separate modules and four case studies. Each of the speakers will be presenting for two hours. The remaining two hours is broken up over the four case studies.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for physicians and other primary care providers to dispense
buprenorphine in office practice for treatment of opioid use disorder. Participation in this training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting, such as those in family practice, general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

**Sponsored in part by the Substance Abuse and Mental Health Services Administration (SAMHSA) and in partnership with the American Academy of Addiction Psychiatry (AAAP), the American Osteopathic Academy of Addiction Medicine (AOAAM) and the American Psychiatric Association (APA)**

Funding for this course was made possible (in part) by 1H79T1022022 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

8:30 a.m.–12:30 p.m.

**Opioid Overdose Prevention and Naloxone Access: Opportunities for Integration into Substance Use Disorder Treatment and Recovery**

Alice Bell, LCSW, Prevention Point Pittsburgh, Pittsburgh, PA  
Sharon Stancilf, MD, Harm Reduction Coalition, New York, NY  
Emily Behar, MS, San Francisco Department of Public Health, San Francisco, CA  
Melinda Campopiano von Klimo, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

This session will be the first public opportunity to learn about the Substance Abuse and Mental Health Services Administration’s (SAMHSA) detailed overdose prevention and response curriculum, which serves to support implementation of strategies discussed in the Opioid Overdose Prevention toolkit and Federal Guidelines for Opioid Treatment Programs. The session will be delivered by four presenters with varied areas of expertise in overdose prevention, recognition, and response.

The presenters will introduce the curriculum, the core concepts, and how to use the curriculum. There will be a discussion of why it is most essential to expand our ability to provide naloxone to those most likely to be present at the scene of an overdose: heroin/opioid users themselves. The presenters will also facilitate discussion of some substance use disorder (SUD) treatment case studies with attendees and various models for integrating overdose prevention in SUD treatment programs and brainstorm some strategies for addressing common barriers.

There will also be a discussion of some of the nuanced details of increasing naloxone access through SUD treatment organizations or collaboration with other organizations in the community. With a sample agency policy as a template, attendees will have the opportunity to develop a policy that fits the context of their respective agencies.

In addition, there will be a discussion about the opioid safety and integrating naloxone access into primary care clinics, including opportunities to collaborate with the primary care providers of SUD patients. Presenters will provide various patient education materials and lead a discussion with attendees about how to decide which materials are appropriate for different contexts and ways to modify the language so that people perceive that they are the intended audience for the materials.

All presenters will facilitate a question and answer session and conclude the session with an explanation of activities and opportunities for overdose prevention support that reflect SAMHSA’s commitment to overdose prevention.

**Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)**

1:00 p.m.–4:00 p.m.

**Medication Assisted Treatment for Pregnant Women with Opioid Use Disorder—Best Practices and Lessons Learned from Kentucky and Massachusetts**

Sherye McManus, PhD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD  
Kris Shera, SMART Initiative, Frankfort, KY  
Laura Sternberger, LICSW, Moms Do Care Project, Boston, MA

This session will present best practices and lessons learned for medication assisted treatment (MAT) for pregnant women who are opioid dependent, as experienced by two current grantees of the Substance Abuse and Mental Health Services Administration (SAMHSA) Medication Assisted Treatment–Prescription Drug and Opioid Addiction (MAT-PDOA) program, Kentucky and Massachusetts.

The presentations will provide an overview of the MAT-PDOA program, including current data and research. The presenters will outline the Supportive Mothers to Achieve Recovery through Treatment and Supports (SMARTS) initiative to address the fifteenfold increase over the last decade in NAS cases in Kentucky. They will demonstrate how they are addressing severe service capacity deficits by establishing wraparound care or integrated health care and recovery services using funds from Medicaid expansion and the Affordable Care Act, as well as the SMARTS initiative. The SMARTS initiative also enhances technology infrastructure for performance reporting and MAT education for service providers.

The presenters will also describe how they have expanded efforts to identify untreated pregnant women who are opioid dependent and provide them access to evidence-based MAT as part of the Moms Do Care Project in Massachusetts. The project focuses on delivering comprehensive, coordinated, integrated, and trauma-informed prenatal and postnatal primary and behavioral health care. Participants receive individualized MAT and recovery services that support their early and sustained recovery and their choices about continuing medication, and support their efforts to maintain custody of or contact with their children.

**Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)**

AATOD Open Board Meeting  
Saturday, October 29 • 5:00 p.m.–8:30 p.m.  
**Supported by Addiction Treatment Providers Insurance Group**
1:00 p.m.–5:00 p.m.

Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Lynne Howell Wiklander, BGS, ECG, Inc, Englewood, NJ

Opioid Treatment Programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to effectively influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately operate in the best interests of our patients and communities.

This session teaches three key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication assisted treatment. These messages resulted from a year-long pilot project, “Communicating Messages that Achieve Results.” Participants will hear these messages and learn how to communicate them in order to create a positive impact within their communities. This session will include Q & A techniques designed to deal with emotional audiences while reinforcing the presentation objectives.

For session effectiveness, participation is limited to the first 50 attendees who arrive for the session.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)

Supported by VistaPharm, Inc.

8:00 a.m.–5:30 p.m.

Opioid Maintenance Pharmacotherapy: A Course for Clinicians

Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Abigail Kay, MD, Thomas Jefferson University, Philadelphia, PA
Brian McCarroll, DO, BIO-MED Behavioral Healthcare, Roseville, MI
Kenneth Stoller, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD

This course is recommended for clinicians who have an interest in increasing their knowledge of medication assisted treatment (MAT) for opioid use disorder. The updated curriculum includes current consensus guidance for best practice treatment for opioid addiction, focusing primarily on utilization of methadone.

Topics include overview of opioid use disorder, epidemiology, opioid pharmacology, evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug-to-drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management, and an overview of other medication modalities.

While the course is primarily intended for clinicians with limited experience in MAT, it also provides updated information for more experienced clinicians. Participants will receive a comprehensive syllabus with reference and resource materials. To further integrate the educational objectives, participants are encouraged to discuss challenging problems and clinical issues to facilitate understanding of didactic principles.

Experienced opioid treatment program Medical Directors will conduct the program, focusing on the goal for participants to acquire the essential knowledge and skills necessary to deliver safe and effective medication assisted treatment for patients with opioid use disorder.

The $235.00 registration fee includes course materials, morning coffee service, and afternoon luncheon.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)

Supported by the National Institute on Drug Abuse
8:30 a.m.–12:30 p.m.

Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Lynne Howell Wiklander, BGS, ECG, Inc, Englewood, NJ

Opioid Treatment Programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to effectively influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately operate in the best interests of our patients and communities.

This session teaches three key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication assisted treatment. These messages resulted from a year-long pilot project, “Communicating Messages that Achieve Results.” Participants will hear these messages and learn how to communicate them in order to create a positive impact within their communities. This session will include Q & A techniques designed to deal with emotional audiences while reinforcing the presentation objectives.

For session effectiveness, participation is limited to the first 50 attendees who arrive for the session.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)

Supported by VistaPharm, Inc.

8:30 a.m.–5:30 p.m.

State Opioid Treatment Authorities’ Meeting
(Closed Session for State and Federal Officials)

Mitra Ahadpour, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Melinda Campopiano von Klimo, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Anthony Campbell, DO, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Wilmarie Hernandez, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Jinhee Lee, PharmD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Mary Lou Ojeda, MS, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Sidney Hairsotn, MSN, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
Ivette Ruiz, MS-CRP, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD

9:00 a.m.–12:00 p.m.

Delivering Integrated Care in the Era of Health Care Reform: Increasing Access to Care Treatment and Services for Improved Outcomes

Megan Marx-Varela, MPA, The Joint Commission, Oakbrook Terrace, IL
Dale Meyer, MS, People Encouraging People, Baltimore, MD

The Behavioral Health Home is an important means by which to unite the diverse components of an individual’s care in order to insure that care, treatment and services provided are accessible, family-centered, continuous, comprehensive, coordinated, compassionate and culturally effective. With the advent of health care reform, an increasing number of behavioral health care organizations have sought to offer integrated primary physical health care for the individuals and families that they serve.

In this workshop we will discuss the decision making process for behavioral health care organizations considering offering integrated care, with a focus on how the provision of medication assisted treatment is included in that process. This will include reviewing a sample of certification standards, and discussing how organizations can achieve compliance with them. For organizations considering obtaining Behavioral Health Home certification this workshop will provide a framework to get started, and for those already certified, it will refine both their understanding of and their approach to offering integrated care.

9:00 a.m.–12:00 p.m.

Extended Release Naltrexone in Parolees, HIV-Infected Patients and Adolescents/Young Adults with a History of Opioid Use Disorder

Petra E. Jacobs, MD, National Institute on Drug Abuse, Center for the Clinical Trials Network, (NIDA/CTN), Rockville, MD
Joshua Lee, MD, New York University School of Medicine, New York, NY
Pamela Vergara-Rodriguez, MD, Ruth M. Rothstein CORE Center, Chicago, IL
Shannon Mitchell, PhD, Friends Research Institute, Baltimore, MD

Current medication options to treat opioid use disorders (OUD) approved by the FDA include opioid agonists (methadone, buprenorphine) and antagonist...
Unfortunately, a variety of factors contribute to the limited number of PWID uptake amongst PWID participants has been low. Despite these facts, HCV treatment 16-42% per year. Recent FDA-approved HCV treatments can cure >90% of 80% depending on frequency and duration of use, while incidence ranges from burden in developed countries. HCV prevalence among PWID is as high as fact, people who inject drugs (PWID) represent the majority of HCV disease 6
AATOD 2016 CONFERENCE

1:00 p.m.–4:00 p.m.

Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders

Stevan Gonzalez, MD, Baylor All Saints Medical Center, Fort Worth, TX
Daniel Fierer, MD, Icahn School of Medicine at Mount Sinai, New York, NY
Lynn Taylor, MD, The Miriam Hospital, Providence, RI
Michael Ninburg, MPH, Hepatitis Education Project, Seattle, WA
Corinna Dan, RN, US Department of Health and Human Services, Washington, DC

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease (CLD) with an estimated global prevalence of more than 150 million, with up to an estimated 3.2 million infected individuals in the United States. Currently, injection drug use is the leading risk factor for HCV acquisition. In fact, people who inject drugs (PWID) represent the majority of HCV disease burden in developed countries. HCV prevalence among PWID is as high as 80% depending on frequency and duration of use, while incidence ranges from 16-42% per year. Recent FDA-approved HCV treatments can cure >90% of patients without the need for interferon. Despite these facts, HCV treatment uptake amongst PWID participants has been low.

Unfortunately, a variety of factors contribute to the limited number of PWID entering HCV care and treatment. Such barriers exist at the patient, physician, and health system levels. Although there are different barriers that are specific to each group, in general these barriers are either 1) based on misperceptions or 2) have become “partially resolved” in the wake of advances in HCV management, healthcare reform including expanded Medicaid coverage for low-income patients, increased pharmaceutical access through public insurance and private indigent care support programs and federal and state government screening mandates. Addressing such barriers is the important first step toward formulating interventions to increase access to care.

The Triple E session will be built around a series of expert-led presentations with the integration of real-world cases serving to highlight and reinforce the recognition of, methods for diagnosing, and the management of HCV. These clinical cases will provide abundant opportunities for audience input, faculty presentation, panel discussion, and debate regarding the best treatment strategies for a given patient. This session emphasizes the need to ensure that PWID have access to viral hepatitis prevention, care, and treatment services; to develop and mobilize community resources that prevent viral hepatitis caused by injection drug use; and to advance research into the prevention of viral hepatitis among persons who use drugs.

Sponsored by the Chronic Liver Disease Foundation and an educational grant from AbbVie and Gilead

1:00 p.m.–5:00 p.m.

Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD): EUROPAD Forum

The World Federation for the Treatment of Opioid Dependence (WFTOD) was founded during the European Opiate Addiction Treatment Association (EUROPAD) meeting of July 2007 in Ljubljana, Slovenia. All of the member nations, which included the member countries of EUROPAD and all of the member states with AATOD, agreed to a charter for the World Federation.

CHAIRMAN: Icro Maremmani, MD, Santa Chiara University Hospital, Pisa, Italy

INTRODUCTIONS: Michael Rizzi, AATOD International Committee Chair, Cranston, RI

1:00 p.m.–1:20 p.m.

Effect of Non-Scheduled Urine Tests among All Students in a Private High School in Las Vegas

Miriam Adelson, MD, Dr. Miriam & Sheldon G. Adelson Clinic For Drug Abuse Treatment & Research, Inc., Las Vegas, NV, USA

1:20 p.m.–1:40 p.m.

Results of the Opioid Substitution Treatment Programs Assessment in Belarus

Alexei Alexandrov, MD, Minsk regional clinical center “Psychiatry-narcology,” Minsk, Belarus
Welcome Reception
Sunday, October 30 • 5:30 p.m.–7:30 p.m.
The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some time reuniting with old friends and colleagues.
Supported in part by Atlantic Diagnostic Laboratories

Draft Guiding Principles for Regulations Governing the Use of Agonist Medication in the Treatment of Opioid Dependence
Kevin Journac, MD, Clinique Liberté, Bagneux, France, EU

Factors Related to High Methadone Dose Among Patients
Mai Hoai Son, MD, Ho Chi Minh AIDS Center, Ho Chi Minh, Vietnam

Educational Intervention for Prevention (from Children to MMT Patients)
Einat Peles, PhD, Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv, Israel

COMPASS Project: Inside and Outside Link for Inmates and Patients Who Inject Drugs with Hepatitis B or C in France
André-Jean Remy, MD, Centre Hospitalier de Perpignan

Knowledge about HIV and Risky Behavior Among Methadone Maintenance Treatment Patients
Anat Sason, MMHOS, Adelson Clinic for Drug Abuse, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Sustainable Methadone Maintenance Treatment Program by Integrated Model–Lesson Learned from Two Clinics
Van Tieu, MD, Ho Chi Minh AIDS Center, Ho Chi Minh, Vietnam

Promoting the Recovery Oriented System of Care in Low Resource Setting: The Case of Vietnam
Hoang Huy Vu, MPH, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

Psychosocial Determinants in the Treatment of Opioid Use Disorder with Buprenorphine
James E. Phelan, LCSW, Veteran Health Administration, Columbus, Ohio, USA

Partnering to Treat Pregnant Women with Opioid Use Disorders. Lessons Learned from a Six State Initiative
Sharon Amatetti, MPH, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Nancy K. Young, PhD, National Center on Substance Abuse and Child Welfare, Lake Forest, CA
Martha Kurgans, LCSW, Virginia Office of Substance Abuse Services, Richmond, VA
Christine Scalise, MA, New Jersey Division of Mental Health and Addiction, Trenton, NJ

This session provides guidance to medication assisted treatment (MAT) professionals on how to work collaboratively with partners to engage and treat pregnant women with opioid use disorders. The presentation will provide guidance on collaboration gleaned from the National Center on Substance Abuse and Child Welfare’s (NCSACW) publication, The Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders. The session will further describe tactics used by two states engaged in the NCSACW two-year In-Depth Technical Assistance (IDTA) initiative on Substance Exposed Infants. The initiative, currently serving six states, is strengthening the capacity of states to serve pregnant women with substance use disorders, particularly those with opioid use disorders and their infants with Neonatal Abstinence Syndrome (NAS). Through the initiative, state partners deepened their understanding of barriers that impede or deter women and infants from receiving care. With technical assistance from the NCSACW, state partners created practice, policy, and protocol changes for effective cross-system service delivery for these women and infants.

Leaders from New Jersey and Virginia will describe how they worked with state MAT providers through the initiative to build communication and information sharing processes with hospitals, home visitors, and child welfare agencies to create a continuum of care for pregnant women and their children. Both states will discuss their work to increase the use of best cross-system practices such as intensive case management, leading to an increase in the engagement of pregnant and post-partum women in services and an increase in the identification of substance-exposed infants and their engagement in early intervention services.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)
EXHIBIT SESSIONS

The AATOD Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 350,000 patients in opioid treatment programs. In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts and refreshment breaks will be held exclusively in the exhibit area. An Exhibitor’s Networking Event will be held Monday, October 31st to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

EXHIBIT HOURS

Sunday, October 30—4:00 p.m.—7:30 p.m.
Monday, October 31—7:30 a.m.—9:30 a.m.; 11:30 a.m.—4:30 p.m.
Tuesday, November 1—7:30 a.m.—1:30 p.m.

EXHIBITORS AS OF JUNE 9, 2016

AATOD
Accumedic
ACM Medical Laboratory
Addiction Treatment Providers Insurance Program
Advanced Clinical Laboratory Solutions
Aeon Clinical Laboratories
Alkermes Inc.
American Drug Screen Corporation
Atlantic Diagnostic Laboratories LLC
BHbusiness
BioDelivery Sciences International
C&C Containers, LLC
CARF International
Clinical Science Lab
Computalogic (Method one)
Comstock Computing LLC
CSS Inc.
IC&RC/PCE
Indivior Inc
IVEK Corporation
Mallinckrodt Pharmaceuticals
Mertz Taggart
Naples Medical Devices
NetaLytics LLC
Netsmart
O.Berk Co. of New England & Kols Containers
OraSure Technologies Inc
Quest Diagnostics
Redwood Toxicology Laboratory Inc
Roxane Laboratories, Inc.
San Diego Reference Laboratory
SMART Management Inc.
TenEleven Group, Inc.
The Braff Group
The Joint Commission
Tower Systems Inc
Treatment Hub 365
Turning Point Clinic
VistaPharm Inc.
Wolters Kluwer Health

The following domestic and international posters will provide valuable research findings to treatment providers:

Effect of Non-Scheduled Urine Tests among All Students in a Private High School in Las Vegas
Miriam Adelson, MD

What is “Treatment” in Drug Courts? A Qualitative Study of Treatment Practices in Indiana Drug Court
Barbara Andraka-Christou, JD

Cannabis, The Anti-Gateway Drug?
Angela Bonaguidi, LCSW

Use of Risk Mitigation Practices by Family Nurse Practitioners Prescribing Opioids for the Management of Chronic Non-Malignant Pain
Sahil Chaudhary, BS Candidate

Implementation of Overdose Education and Naloxone Distribution (OEND)
Emily Daniell, BSN

Racial/Ethnic Differences in Primary Drug used among Entrants to Opioid Treatment Programs over Time
Chunki Fong, MS

Characterizing Opioid and Benzodiazepine Abuse as Reported by Opioid Treatment Programs in the United States
Jody L Green, PhD

Posters are in place at all times when the Grand Ballroom is open. Authors will present their topic on Monday, October 31 from 7:30 a.m.—8:45 a.m. and 3:00 p.m.—4:00 p.m.
Characterizing Opioid and Benzodiazepine Abuse as Reported by Patients Entering Medication-Assisted Substance Abuse Treatment Programs in Europe
Jody L Green, PhD

HUB and Spoke Model of Care
Evan Kletter, PhD

Usefulness of a Brief Educational Event to Challenge Service Providers’ Approaches with Families
Jan Ligon, PhD

A Study of Factors Contributing to Drug Court Graduation
David Masri, PhD

Characteristics and Treatment Outcomes among Pregnant Women Maintained on Buprenorphine vs. Methadone
Krystle McConnell, BA

Decisions in Recovery: Medications for Opioid Addiction - A Web-Based Shared Decision Making Tool
Niki Ann Miller, MS

“No Thanks”: When OTP Patients Refuse a Naloxone Kit for Overdose Prevention
K. Michelle Peavy, PhD

Stress among Methadone Maintenance Treatment Patients, Prevalence and Risk Factors
Einat Peles, PhD

Knowledge about HIV and Risky Behavior among Methadone Maintenance Treatment Patients
Anat Sason, MS

The Effectiveness and Reproducibility of a Learning Collaborative Strategy to Improve Quality of Care for Rural Buprenorphine Patients with Opioid Use Disorders
Elizabeth Saunders, MS

Controlled Substance Monitoring with the Prescription Monitoring Program (PMP) in an Office Based Buprenorphine Program
Julia Shi, MD

How Do Peer Recovery Services Groups Work? An Interactional Analysis
Jo L. Sotheran, PhD

Increasing Access to Hepatitis C Treatment for Opioid Maintained Patients via Telemedicine
Clewert Sylvester, MD

Staff Attitudes and Perceptions Supportive of Overdose Prevention Education in an Opioid Treatment Program
Rosson Wiebe, DNP

Optimal Minimum Length of Treatment with Buprenorphine: An Analysis of Resource Use and Costs after Medically Controlled Discontinuation
Vladimir Zah, PhD(c)

“No Thanks”: When OTP Patients Refuse a Naloxone Kit for Overdose Prevention
K. Michelle Peavy, PhD

“Methadone is Making Me Fat!”: Addressing Patients’ Concerns about Methadone and Weight Gain
Cassie Zwart, MSW

Johns Hopkins Cornerstone at Helping Up Mission: A Novel Community-Academic Partnership
Denis Antoine, MD

Combatting Opioid Overdose
Kelly Dunn, PhD
Monday, October 31, 2016

OPENING PLENARY SESSION
8:45 a.m.–10:15 a.m.

The Opioid Crisis—Urgent Need for Timely Action

MODERATOR:
Vickie L. Walters, LCSW-C, Executive Director, IBR/REACH Health Services, Baltimore, MD

KEYNOTE SPEAKERS:
Honorable Larry Hogan, Governor of Maryland, Annapolis, MD (Invited)
Barbara J. Bazron, PhD, Executive Director, Behavioral Health Administration (BHA), Baltimore, MD
Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc. (AATOD), New York, NY
Peter Bruun, Founder, New Day Campaign, Towson, MD
Gilberto Gerra, MD, Chief, Drug Prevention and Health Branch, Division of Operations, United Nations Office on Drugs and Crime (UNODC), Vienna, Austria

The Opening Plenary Session will review AATOD’s projects and keynote efforts in Maryland and across the globe. Ms. Vickie Walters, LCSW-C, Conference Chairperson and Program Director, REACH Health Services at Institutes for Behavior Resources Inc. in Baltimore, will welcome conference attendees and provide an overview of this exciting conference. Ms. Walters will be followed by a very special welcome to Maryland by The Honorable Larry Hogan, Governor of Maryland. Governor Hogan will discuss his heroin taskforce, key findings, and recommendations for addressing this epidemic. Dr. Barbara Bazron will discuss Naloxone and Legislative Partnerships in the city of Baltimore. Mr. Mark Parrino, AATOD President, will follow, providing an overview of the challenges, opportunities, and accomplishments of AATOD over the past 18 months and into the future. Peter Bruun, Founder, New Day Campaign, will discuss the engagements of individuals, treatment providers, families, and communities through the arts, to start a discussion and decrease stigma. Gilberto Gerra, Deputy Director, UN Office on Drugs and Crime, will describe international struggles with opioid addiction and the ways it is being addressed.

A1 Methadone 101
Laura F. McNicholas, MD, University of Pennsylvania, Philadelphia, PA
Kenneth B. Stoller, MD, Johns Hopkins University, Baltimore, MD
Yngvild Olsen, MD, Institutes for Behavior Resources, Inc., Baltimore, MD

Methadone maintenance treatment within the setting of comprehensive opioid treatment programs (OTPs) has been available for decades. Yet many clinicians and policymakers do not understand how and why it is effective in treating opioid use disorder (OUD). The presenters will review the basic elements of opioid agonist treatment, examine the pharmacologic aspects of methadone, present initial screening, admission, and assessment techniques; describe associated medical, psychiatric, and substance use conditions associated with OUD; describe the efficacy of methadone maintenance; review other OUD pharmacotherapies; and review the continuum of routine and wrap-around services that are provided in OTPs.

*Foundations of MAT

A2 Addressing the Reproductive Health Needs of Women in SUD Treatment
Mishka Terplan, MD, Behavioral Health System Baltimore, Baltimore, MD

Women with substance use disorder (SUD) have unmet reproductive health needs. Although the Substance Abuse and Mental Health Services Administration promotes integration as central in reducing costs and improving care for individuals with behavioral health conditions, little attention has been placed on the incorporation of family planning in SUD treatment. This workshop will 1) review the unique reproductive health needs of women with SUD and 2) present the findings from a novel pilot study integrating reproductive health screening, education, and service delivery into SUD treatment. Attention will be placed not only on the public health relevance, but also on cost effectiveness of integration strategies and ethical considerations.
1:30 p.m.–3:00 p.m.

HOT TOPIC ROUNDTABLES

Hot Topic Roundtables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support, and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

Experienced leaders in the field will be facilitating these sessions.

Substance Abuse and Mental Health Services Administration Regulatory Update
Facilitator: Sidney Hairston, MSN

Mergers & Acquisitions: Good for Patients?
Facilitators: Jason Kletter, PhD and Kellie Rollins, PsyD

Getting the Political Process to Work for People in Recovery: Platform Review
Facilitator: Legal Action Center

Confronting Stigma and Discrimination in Treatment
Facilitator: Robert Lambert, MA

What have you done in your community: Building Recovery Partnerships
Facilitators: Zac Talbott, CMA and Ivette Torres, MEd, MS

1:30 p.m.–3:00 p.m.

WORKSHOP SESSIONS

#1 Key Issues on Perinatal Opioid Dependence and Neonatal Abstinence Syndrome
John J. McCarthy, MD, University of California, Davis, Tahoma, CA

Perinatal opioid dependence presents many challenges for clinicians including the presence of Neonatal Abstinence Syndrome (NAS). The pharmacokinetic science of methadone/buprenorphine dosing in pregnancy and novel use of serum methadone/metabolite ratios as a tool for assessing dynamic metabolic changes in the perinatal period are important for the proper treatment of mother and baby. The concepts of ‘fetal opiate receptor occupancy’ and ‘repetitive intrauterine stress’ will be introduced as factors that effect neonatal health and NAS risks. This presentation will provide clinicians with the knowledge to treat the mother/infant dyad with current strategies to reduce stress upon both of them.

A3 Confronting Opioid Overdose in the OTP: Putting Policies into Practice and Naloxone to Use
Robert Roose, MD, Sisters of Providence Health System, Holyoke, MA
Janet J. Stabile, LICSW, Sisters of Providence Health System, Holyoke, MA
Gwen Fenton, RN, Sisters of Providence Health System, Holyoke, MA

Inpatient and outpatient Opioid Treatment Programs (OTPs) have a critical role in prevention of opioid overdose. Patients in OTPs are at higher risk of overdose upon initiation or discontinuation of treatment and with concomitant substance use. Programmatic and other barriers have prevented many OTPs from realizing their potential in regards to patients, staff, and community education; overdose prevention planning; and naloxone distribution. This workshop uses concrete examples of putting state and program-level policies into action in an OTP to prevent opioid overdose and increase naloxone uptake. Ideas and tools for best practices will be discussed and provided.

A4 Strengthening the Partnership between OTPs and the Child Welfare System
Anne Gold, MSW, Illinois Department of Children and Family Services, Volo, IL
Rita Houston, MSW, Illinois Department of Children and Family Services, Chicago, IL
Richard Weisskopf, BS, Illinois Department of Human Services, Chicago, IL

The workshop will provide a description of the development and implementation of training for Illinois child welfare staff to increase their knowledge of current evidence-based practices in opioid dependence treatment; build their competence in supporting patients’ engagement in treatment; and provide them with the skills on safe medication storage for home visits with families. Training outcome data will also be shared including participant testimonials. The presenters will describe the program from initial concept to implementation utilizing a PowerPoint presentation and handouts.

A5 Integrated Care and the Health Home: Lessons Learned from a Maryland OTP
Angela Fulmer, MSN/MPH, Institutes for Behavior Resources, Inc., Baltimore, MD
Molly Greenberg, RN, Institutes for Behavior Resources, Inc., Baltimore, MD
Yngvild Olsen, MD, Institutes for Behavior Resources, Inc., Baltimore, MD

The Health Home is a care model that Opioid Treatment Programs (OTPs) may employ to increase their capacity to provide integrated care and ultimately improve treatment, overall health outcomes, and patient quality of life. There are many barriers to Health Home implementation but with the right knowledge and tools, provider organizations can successfully integrate this model of care. This workshop will introduce attendees to the Health Home concept and describe one operational model for the Health Home, utilizing the implementation of the Health Home in a Maryland OTP as an example. Presenters will share outcomes, best practices, and lessons learned.
4:00 p.m.–5:30 p.m.

WORKSHOP SESSIONS

B1 Ending Stigma’s Harm: Patients and Providers United for Health and Recovery
Herman Joseph, PhD, Stop Stigma Now, New York, NY
Joyceyln Woods, MA, NAMA Recovery, New York, NY
Zac Talbott, CMA, Counseling Solutions of Chatsworth, Chatsworth, GA and NAMA Recovery, TN/GA Chapter

From the start of methadone treatment, patients have faced an increasing and pervasive social stigma comprised of misleading media, major social institutions, family, and friends. Prejudice and stigma have become the primary social forces confronting patients in Medication Assisted Treatment (MAT). For quality MAT to fulfill its potential, it will be necessary to challenge and end this negative influence. The various prejudices that patients face in their road to recovery include: language, family, criminal justice system, child welfare, health care, education, employment, life insurance, etc. The workshop concludes with strategies to end the stigma that patients experience.

*B1 Foundations of MAT

B2 Integrating Mindfulness Based Parenting into an Opioid Treatment Program
Diane Abatemarco, PhD, Thomas Jefferson University, Philadelphia, PA
Meghan Gannon, PhD, Thomas Jefferson University, Philadelphia, PA

The “Practicing Safety Mindfulness Project for Mothers in Drug Treatment” is a federally funded multi-faceted intervention aimed at reducing the toxic stress children of families with substance use disorders endure. One dimension of this intervention is the implementation of a 12-week mindfulness based parenting intervention for mothers of children aged 3 to 36 months. This workshop describes the integration of mindfulness into an opioid treatment program. Participants will also experience mindfulness-based stress reduction practices. Lastly, findings and results will be provided that demonstrate the effect of the intervention on individual psychosocial, parenting, and maternal domains.

*B2 Integrating Mindfulness Based Parenting into an Opioid Treatment Program

B3 What to Do When Courts, Insurers and Others Block Effective Treatment
Sally Friedman, JD, Legal Action Center, New York, NY
Karla Lopez, JD, Legal Action Center, New York, NY
Melissa Trent, JD, Legal Action Center, New York, NY

Individuals often cannot access medication assisted treatment (MAT) because criminal justice and child welfare agencies will not allow it and insurers will not cover it. This workshop explains how to overcome these barriers. The presenters will explain legal mandates and advocacy strategies featured in Legal Action Center’s two groundbreaking reports, “Medication-Assisted Treatment in Drug Courts: Recommended Strategies” and “Health Insurance for Addiction & Mental Health Care: A Guide to the Federal Parity Law.” Participants will learn how to work with courts and others to permit MAT and how to identify and challenge parity violations.
B4 Integrating HCV Care into a Opioid Treatment Program
Lynn E. Taylor, MD, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, RI
Sophie Sprecht-Walsh, LPN, CODAC, Inc./University Medicine, Cranston, RI
Linda Hurley, LCDCS, CODAC, Inc., Providence, RI

People who inject drugs have the highest incidence/prevalence of HCV, yet a minority of HCV-infected persons with opioid addiction undergoes HCV treatment. Presenters will discuss implementation of an on-site HCV clinic at CODAC, an Opioid Treatment Program (OTP) in Providence, RI, and how on-site HCV care in OTPs overcomes barriers to treatment. HCV clinic outcome data will be presented, including cure rates and consequences of late diagnosis. We will also discuss the potential benefits for staff utilization and improved patient outcomes. Participants will learn how to replicate all or part of the initiative at their own programs.

B5 How to Prevent Employment Discrimination and Harassment Claims
Kathryn J. Russo, Esq., Jackson Lewis P.C., Melville, NY

This workshop will provide practical advice to employers on preventing discrimination, harassment, and retaliation in the workplace—in several different contexts. The presenter will discuss best practices with respect to lawful hiring; why written performance evaluations are critically important and how to write them so that they protect your organization from legal claims by employees, and how to handle internal complaints of discrimination and retaliation made by employees. Additionally, the speaker will address how to discipline employees; evaluate the appropriate severity of discipline, up to and including termination; and how to document disciplinary actions properly to avoid potential lawsuits from employees.

6:30 p.m.–8:30 p.m.
The New Day Campaign: Where Stigma Ends, Healing Begins
Peter Bruun, New Day Campaign, Towson, MD
Robert Schwartz, MD, Friends Research Institute, Baltimore, MD

The strategy of the session, The New Day Campaign: Where Stigma Ends, Healing Begins, is to bring participants together with art, heart, and humanizing. Once participants are in a place of caring and healing, discussion of the many aspects of dealing with stigma and paths to action will lead to participants leaving with the motivation and information to work in their communities, programs, and personal lives on ending stigma for those with substance use disorders. The presentation is interactive and includes time for reflection, discussion, and engagement with the presenters and the audience. The presentation includes a presentation of evidence-based treatment models, meditation, poetry, filmography, audiography, song, visual arts and conversation meant to inspire, engage, and question, and a discussion of the dance between art, healing, and anti-stigma.

Sponsored by Friends Medical Laboratory, Inc. and Institutes for Behavior Resources, Inc.–REACH Health Services
C3 Maricopa County Correctional Health Methadone Program

Jeffrey Alvarez, MD, Maricopa County Correctional Health Services, Phoenix, AZ
Rick Christensen, PA, Community Medical Services, Phoenix, AZ
Michael C. White, MCI, Community Medical Services, Phoenix, AZ

Dr. Alvarez, the Director of Maricopa County Corrections, will address the process of developing a jail Opioid Treatment Program, collaborating with a community provider, and expanding medication assisted treatment to include all jail populations/demographics, along with Maricopa County Drug Courts and local Diversion Programs. Rick Christensen of Community Medical Services will discuss the development and implementation steps required to create the proper continuum of care and changes in culture needed to sustain the program. Michael White will discuss the Collective Impact Model along with Community Based Services to better support patients navigating multiple systems, accessing needed resources, and establishing a foundation of community partners.

C4 Pharmacotherapy Update: Cardiac Safety Considerations Beyond Methadone and the Role of Psychiatry in Implementation of a Cardiac Safety Program

Mori J. Krantz, MD, Denver Health, Denver, CO
Mark C.P. Haigney, MD, Uniformed Services University, Bethesda, MD
Megan A. Marx-Varela, MPA, Joint Commission, Oakbrook Terrace, IL

Cardiac and central nervous system (CNS) safety of opioid agonist therapy is increasingly scrutinized given rising opioid-related fatalities. Knowledge gaps exist regarding the risk of cardiac toxicity of drugs beyond methadone and buprenorphine. A number of over the counter preparations appear to have a QTc-prolongation liability. Numerous drug-drug interactions may increase this liability. These will be presented in categories for practical implementation. We will also discuss the implementation of a collaborative training of psychiatrists that include ECG interpretation with oversight by cardiologists. This training proved to be preliminarily successful. These activities are supported by ongoing quality and accreditation processes in Opioid Treatment Programs.
**C5 Challenges to Opioid Treatment Providers after Hurricane Sandy**

Harlan Matusow, PhD, National Development and Research Institutes, New York, NY  
Ellen Benoit, PhD, National Development and Research Institutes, New York, NY  
Andrew Rosenblum, PhD, National Development and Research Institutes, New York, NY

During and after Hurricane Sandy, methadone maintenance patients faced obstacles to obtaining treatment. This session describes ways in which Opioid Treatment Program (OTP) staff anticipated and responded to service disruptions (based on evaluations of emergency plans and interviews with staff, administrators, and State officials; State Opioid Treatment Authorities (SOTAs)) and, patient and drug user experiences during and after the Storm (based on focus groups with patients and out-of-treatment drug users). Recommendations, evaluated for usability and feasibility by a nationwide sample of OTP directors and SOTAs, for improving continuity of care in future emergencies are presented. Key areas of focus include Communication, Transportation, and Technology.

**D3 The Five-Year Recovery Standard for Medication Assisted Treatment**

Robert L. DuPont, MD, Institute for Behavior and Health, Inc., Rockville, MD  
Wilson M. Compton, MD, National Institute on Drug Abuse, Rockville, MD

Sustained five-year recovery as a primary measure of substance use disorder (SUD) outcomes can reshape both treatment outcome research and clinical practice. In this context, the definition of recovery is that of the Betty Ford Institute Consensus Panel, including no use of alcohol, marijuana or other drugs of abuse. The use of medications as prescribed in medication assisted treatment (MAT) is fully compatible with recovery. Physician health programs serve as a model of chronic disease management for SUDs, including opioid use disorders. Use of the five-year recovery standard will encourage all treatment programs to focus their attention on long-term patient outcomes.

**D4 Public Health Solutions for Opioid Addiction and Overdose**

Leana Wen, MD, Baltimore City Health Department, Baltimore, MD  
Adrienne Breidenstine, MSW, Behavioral Health System Baltimore, Baltimore, MD  
Natanya Robinowitz, MSPH, Behavioral Health System Baltimore, Baltimore, MD

Baltimore declared opioid overdose a public health emergency and is leading one of the most aggressive opioid overdose prevention campaigns across the country. With 19,000 active heroin users, and far more who misuse opioids, Baltimore cannot be healthy without addressing this problem. This workshop will focus on Baltimore’s opioid addiction and overdose response plan and the opportunities and challenges involved in implementing a community-focused plan to address this epidemic.

**D1 Meeting the Needs of Patients with Co-Occurring Disorders: Skills for Counselors**

Joan E. Zweben, PhD, University of California, San Francisco & EBCRP, Berkeley, CA

This workshop is intended to acquaint new counselors with key elements of treatment for people with co-occurring disorders and provide an update for existing counselors, including a brief review of research evidence supporting certain approaches. The workshop will begin with brief comments on the epidemiology of co-occurring disorders, barriers to addressing them, and how untreated psychiatric conditions affect recovery and quality of life. The basic principles for distinguishing between substance-induced symptoms and independent disorders, as well as a focus on disorders common in opioid dependent patients, such as anxiety disorders (especially PTSD), and mood disorders (especially depression), will be discussed. We will also review screening and assessment of suicide risk from the perspective of agency protocols as well as the role of the counselor.

*Foundations of MAT

**D2 Mobile Health Apps to Address Opioid Use Disorders**

Doris Titus-Glover, PhD, Optimal Solutions Group, LLC, College Park, MD  
Kate Durocher, BA, Abt Associates, Bethesda, MD

The literature notes that mobile phones and mHealth applications present a significant opportunity to provide patients with substance use disorders with evidence-based treatment. Researchers and government agencies have begun to explore the use of mHealth to address a number of chronic conditions, including substance use disorders and HIV. Specifically, the Substance Abuse Mental Health Services Administration (SAMHSA) has hosted several challenge grants to develop innovative solutions to address opioid use disorders. In addition, SAMHSA is exploring the feasibility of utilizing mHealth as a recovery support for patients in MAT programs. In this session, presenters discuss the opportunity technology based solutions provide to addressing opioid use disorders.
D5 Retaining Patients While They Contemplate Change: A Model to Curb Discharge
K. Michelle Peavy, PhD, Evergreen Treatment Services, Seattle, WA
Paul Grekin, MD, Evergreen Treatment Services, Seattle, WA
Molly Carney, PhD, Evergreen Treatment Services, Seattle, WA

Opioid Treatment Programs (OTPs) face a dilemma when it comes to discharging or not discharging unstable drug using patients. Premature death looms as a possible outcome for discharged patients; however, dangling the threat of discharge can serve as a powerful motivator for change. Furthermore, active drug users may be perceived as hazardous to a safe and therapeutic environment. In this workshop we will: describe an OTP policy that enhances retention by discontinuing discharge due to ongoing drug use; examine how this policy change affected the milieu; and discuss clinical implication of this policy in the context of the current heroin epidemic.

3:15 p.m.–4:45 p.m.
International Presentations: Risks of an Inadequate Methadone Maintenance Protocol

SPEAKERS
Icro Maremmani, MD, Santa Chiara University Hospital, University of Pisa, Pisa, Italy
Angelo Giovanni Icro Maremmani, MD, School of Psychiatry, University of Pisa, Italy
Matteo Pacini, MD, G. De Lisio Institute of Behavioural Sciences, Pisa, Italy

Alcohol Abuse in Heroin Use Disorder Patients: An Unfolding Metabolic Destiny

The presenters, on the basis of their clinical experience, suggest that poly drug abuse in heroin addicts could be correlated with condition of opiate dependence improperly compensated by street heroin or by agonist opioid treatment dosages. Thus the search for an appropriate methadone dosage is crucial not only because it enhances patients’ retention rate within the treatment group, allowing an improvement in social rehabilitation, but also because it reduces the risk of poly drug abuse.

Former Heroin Use Disorder Patients Now Alcohol Use Disorder Patients (FHA-AUD): Addiction History and Clinical Feature

The prevalence of FHA-AUD patients is not negligible. This may relate to previous inadequate treatment of heroin addiction contributing to the development of severe AUD. For these patients we propose a reconsideration of ‘soft’ (low dose) agonist opiate treatment.

Treatment of Alcohol Misuse during Methadone Treatment and Treatment of Alcohol Misuse in Former Heroin Use Disorder Patients

After reviewing the data in the literature on the use of Gamma Hydrossibutiric Acid (GHB) in alcoholics and other kinds of abusers, several cases of alcohol-abusing heroin addicts will be described, in which adequate dosages of methadone and the use of GHB proved to possess some effectiveness, even if there were major limitations regarding compliance and completeness of response. In responding to the challenge of identifying different alcoholic sub-groups that can benefit from specific treatment, we want to shed light on the idea that alcoholics with a history of heroin use should be considered a specific group, and a treatment target should be set on the rebalancing of the opioidergic system after passing through agonist opioid treatment.
The Nyswander/Dole “Marie” Awards will be presented by Jerome H. Jaffe, MD.

The 2016 American Association for the Treatment of Opioid Dependence Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award.

Ray Caesar, LPC, Oklahoma

Ray Caesar has worked in the addictions field for over 30 years as a clinician, educator, consultant, author, and program director. Mr. Caesar was the 2012 recipient of the Oxford House Tom Fellows Award and the 2016 Lydia Nore Excellence Award presented by the Oklahoma Drug and Alcohol Professional Counselor Association. As Oklahoma’s SOTA, Mr. Caesar has made extensive efforts to increase access to medication-assisted treatment, and to combat stigma. Mr. Caesar worked to change state regulations to encourage opening of new programs, and played a fundamental role in the creation of OKATOD and in supporting an anti-stigma campaign during their first year in existence. He helped build a positive working relationship between drug courts and OTPs. Mr. Caesar is now advocating and working with the state on Medicaid reimbursement to increase access even further. Because of Ray Caesar, the state of Oklahoma is a better place for opioid treatment.

Spencer Clark, MSW, North Carolina

Spencer Clark has provided over 27 years of state leadership in addiction treatment and recovery, including development and implementation of state-of-the-art outcomes systems, to Opioid Treatment Providers and patients in North Carolina to ensure funding for both education and advocacy in the provision of treatment and recovery support. Mr. Clark fosters a culture of partnership and networking between the SOTA and the members of NCAOTOD. Under his leadership, the two entities work together to continuously improve the quality and availability of services to those in need. Mr. Clark developed a peer system for opioid treatment physicians statewide to provide support, consultation, training, and standards for safe opioid prescribing. Mr. Clark is a driving force in our field; his passion, compassion and dedication are unmatched. His genuine concern for the population served in NC, including the very special people who work in the field, is evident in all that he does for opioid treatment.

Alice Gleghorn, PhD, California

Alice Gleghorn, PhD, is the Director of the Santa Barbara County Department of Behavioral Wellness. Prior to this directorship, she worked for the San Francisco Department of Public Health for 20 years where she developed innovative programs to improve the health and recovery of people who were opioid dependent. She was instrumental in the expansion of groundbreaking medication-assisted programs for underserved communities while ensuring that uninsured and publicly insured patients in the San Francisco safety net have same-day access to medication-assisted treatment in multiple venues, and that treatment is not discontinued in San Francisco jails. Her leadership created a culture of compassion, outreach, treatment on demand, and equitable access to needed services, including methadone maintenance, buprenorphine maintenance, syringe access, and naloxone overdose rescue. Dr. Gleghorn’s tenacity and diligence in advocating and implementing pioneering evidence-based models has changed the treatment landscape in San Francisco.

Robert Kent, Esq., New York

Robert Kent, Esq., is the General Counsel for New York State Office of Alcoholism and Substance Abuse since 2007 where he provides overall legal support, guidance, and direction to the Executive Office and all divisions of the agency. A graduate of Syracuse University College of Law, Mr. Kent has achieved a long list of important accomplishments while serving as General Counsel, including overseeing the transition to Medicaid Managed Care, negotiating a model contract with the health plans protecting Opioid Treatment Programs (OTPs) and establishing them as essential providers, implementing new streamlined regulations which provide significant regulatory relief to providers and patients, support of medication-assisted treatment, helping to establish a reimbursement rate for buprenorphine in OTPs, support for peer-recovery and establishing new OTPs in areas of unmet need. Despite his many responsibilities, he is never too busy to engage with a concerned patient and assist them in their time of need. His constant focus on the betterment of the opioid treatment system and those impacted by opioid addiction is inspirational.

Robert Lambert, MA, Connecticut

Robert Lambert began his career 29 years ago as a counselor at the Connecticut Counseling Centers (CCC) and currently serves the organization as the President/Executive Director. The work accomplished over time within the Opioid Treatment Program (OTP) include creating innovative intensive outpatient programs, presenting at numerous venues to reduce stigma, and serving on numerous state and federal planning committees. Mr. Lambert established the Connecticut Certified Alcohol and Drug Counseling Training Program (CT-CADAC-TP). The curriculum includes 360 hours of training in treating substance use disorders and co-occurring mental health disorders where 600 students have attended the program since 1995. He also developed a peer mentoring program specific for OTP’s called “Bridge to Recovery.” This program was recognized by the Connecticut Department of Mental Health and Addiction Services (DMHAS) as an innovative model program. The Substance Abuse and Mental Health Services Administration also honored Mr. Lambert with the 2012 Science and Service Award for this program, which has been featured in national publications.

Richard Moldenhauer, MS, Minnesota

Richard Moldenhauer has been in the field treating addictions for 33 years. He has served as the State Opioid Treatment Authority (SOTA) for the last 15 years in Minnesota, is on the faculty at two graduate school training programs and has served this nation in the military. He is recognized for his encyclopedic knowledge of regulations, a deep commitment to serving patients in need of treatment, and not being afraid to take political risks. Mr. Moldenhauer has presented at state conferences and participated in the Minnesota Public Broadcasting Service presentation series, “Heroin at Home: Rise of Opiate Use” and “Heroin at Home: Response to Opiate Use.” In 2011, he was instrumental in declaration of the public health emergency on three Indian reservations and the resolution to gain greater tribal acceptance to provide MAT. He has successfully advocated for patients in Opioid Treatment Programs against burdensome regulation, increased the access for naloxone, and continues to assure accessibility for treatment.

Einat Peles, PhD, Israel

Dr. Einat Peles is a clinical Epidemiologist and the Research Director of the Research Unit at the Adelson Clinic for Drug Abuse Treatment & Research, in Tel Aviv Sourasky Medical Center in Israel, and a senior lecturer in Department of Psychiatry in the Sackler Faculty of Medicine at Tel Aviv University. Involved in the addiction field for more than 10 years, she is a leading researcher in the area of opioid addiction, concentrating on methadone maintenance patients. She conducts epidemiological and longitudinal studies in the areas of retention, hepatitis C seroconversion from her clinic, and a “twint” clinic in Las Vegas. Dr. Peles published more than 50 peer-review scientific papers specifically dealing with methadone maintenance treatment, pain, sleep, cognitive, and psychiatric comorbidity. A QTC monitoring report was accepted by the Ministry of Health and later incorporated.
into national regulation. As a member Adjunct Faculty at the Laboratory of the Biology of Addictive Diseases, Rockefeller University, she is also involved in genetic studies. Dr. Peles recently received the Chimera Award at EUROPAD’s most recent conference held in Leiden, Netherlands.

Kenneth Stoller, MD, Maryland
Dr. Kenneth Stoller is Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and Director, Broadway Center for Addiction, Johns Hopkins Hospital. Dr. Stoller’s transformational leadership at the Broadway Center for Addiction positioned his program to be widely recognized as a center of excellence with outstanding wraparound services that include housing, psychiatric care, primary health care coordination, in-house occupational therapy, embedded MCO case management, and peer recovery services. His contributions to the field range from addictions psychiatry expert, researcher, administrator, educator, mentor, and provider of direct and empathetic patient care. Dr. Stoller has been instrumental in shaping drug related policy, advocating for the cost-effectiveness and cost-benefit of addiction treatment and implementing innovative and integrative addiction treatment modalities. Dr. Stoller has the unique ability to uphold simultaneously the highest standard of both compassion and professionalism in working with patients and colleagues, leaving a mark of inspiration and empowerment on the lives of those he touches.

Trusandra Taylor, MD, Pennsylvania
Trusandra Taylor, MD, has worked in the field of addiction medicine, behavioral health, and managed care, involving all levels of substance use disorder and primary care for over 30 years. She has made major contributions as a patient advocate and medical educator for the safe and efficacious use of methadone in the United States and internationally. Dr. Taylor has served as the course director for the American Association for the Treatment of Opioid Addiction Clinicians Course on Pharmacotherapy since 1997, an expert panel member for the Substance Abuse and Mental Health Services Administration for Substance Abuse Treatment, the Workgroup on Methadone and Cardiac Effects, the Workgroups for Opioid Treatment Program Physician Training and Development of Methadone Induction and Stabilization Guidelines, and served as a consensus panel member for the Treatment Improvement Protocols (TIPS) #43. As a contributor to the literature in a variety of contexts, her name will, no doubt, be recognized in the field of treatment for opiate disorders for many generations to come.

Hoang Van Ke, MD, Vietnam
In Vietnam, Dr. Hoang Van Ke is regarded as a pioneer for his work in the area of medication assisted treatment (MAT) for individuals with opioid use disorders. In 2008, as the Vice Chairman of the Hai Phong Province Peoples Committee, he led the initiative to demonstrate that a Methadone Clinic pilot program could be established and effective in treating individuals in need of medication assisted therapies. During this period, only six clinics were piloting MAT in Vietnam. His continuing efforts have led to expansion of the use of methadone with now over 250 clinics throughout Vietnam, serving more than 45,000 patients. Dr. Ke has collaborated with the MARS Training Institute to pilot recovery support services for patients and staff in Hai Phong. He has facilitated systems change to bring methadone patients and addicts in recovery into health care facilities and community activities in order to reduce stigma. This transformation of the drug treatment system has resulted in community-based, voluntary treatment services where none previously existed for individuals with substance use disorders.

FRIEND OF THE FIELD AWARD
The prestigious Friend of the Field Award was established by AATOD’s Board of Directors. This award recognizes extraordinary contributions to the field of opioid treatment by an individual whose work, although not directly related to opioid treatment, has had a significant impact on our field. The 2016 Friend of the Field Award has been awarded to:

Michael P. Botticelli, MEd, Director, White House Office of National Drug Control Policy (ONDCP)
Michael Botticelli was sworn in as Director of National Drug Control Policy at the White House on February 11, 2015, after being unanimously confirmed by the Senate. Mr. Botticelli has more than two decades of experience supporting Americans affected by substance use disorders. He has encouraged the millions of Americans in recovery today to make their voices heard and confront the stigma associated with substance use disorders, which often keeps individuals from seeking and receiving treatment.

In response to the national opioid epidemic, Mr. Botticelli has coordinated actions across the Federal government to reduce prescription drug abuse, heroin use and related overdoses. These include supporting community-based prevention efforts; educating prescribers and the public about preventing prescription drug abuse; expanding use of the lifesaving overdose-reversal drug naloxone by law enforcement and other first responders; and increasing access to medication assisted treatment and recovery support services to help individuals sustain their recovery from opioid use disorders.

RICHARD LANE/ROBERT HOLDEN PATIENT ADVOCACY AWARD
Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike. Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of AATOD, succeeding Richard Lane’s term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Brenda Davis, MSW
For approximately 20 years, Brenda Davis has been employed as a patient advocate and has assumed duties as treasurer of NAMA Recovery. She was instrumental in establishing the MARS Project in the Mount Sinai/Beth Israel Methadone program and has been in recovery nearly three decades. Brenda has mastered the medical and social aspects of methadone maintenance including: stabilization, side effects, and drug interactions; the major health concerns of patients including pregnancy, pain, infectious diseases; and the personal and social issues including the pervasive stigma which patients encounter in the course of their treatment and lives.

She has attended conferences and participated in policy meetings with various governmental agencies. The administration of the Mount Sinai/Beth Israel Methadone program has also been impressed with the breadth of her knowledge and her capacity to help settle problems which arise in the clinics between patients and the staff, issues that arise in the patients’ families, and criminal justice matters.
Prisoners with Substance Use Disorders (SUD) have unique challenges in accessing treatment after release. This is partly because newly- released inmates at high risk for opioid overdose death or return to criminal activity and re-incarceration. This workshop will present recently completed trials of buprenorphine and extended release naltrexone for pre-release prisoners in Baltimore and provide practical implications of research findings, the unique challenges of linking these medications to prisoners, and to community programs after release.

**E2 Using Medications to Treat Opioid Dependence among Prisoners**

Michael S. Gordon, DPA, Friends Research Institute, Baltimore, MD
Terrence T. Fitzgerald, MD, Glenwood Life Counseling Center, Baltimore, MD
Robert P. Schwartz, MD, Friends Research Institute, Baltimore, MD

In the US, there are over 1.5 million state and federal prisoners, of whom an estimated 15% have histories of opioid dependence. Despite the availability of effective FDA-approved medications most opioid-dependent inmates remain untreated. As a consequence, opioid use resumes rapidly placing newly-released inmates at high risk for opioid overdose death or return to criminal activity and re-incarceration. This workshop will present recent completed trials of buprenorphine and extended release naltrexone for pre-release prisoners in Baltimore and provide practical implications of research findings, the unique challenges of providing these medications to prisoners, and to linking patients to community programs after release.

**E3 Federal Addiction Policy: Building on our Accomplishments and Looking Ahead**

Gabrielle de la Guerinnierre, JD, Legal Action Center, Washington, DC
Paul Samuels, JD, Legal Action Center, New York, NY

The addiction care system continues to face tremendous change and upheaval. While we have a certain degree of clarity about the legal and regulatory framework of the Affordable Care Act and the parity law, much work remains to fully implement both laws and to ensure that their consumer protections are adequately enforced. As we approach a new presidency and a new Congress, this workshop will review recent developments at the federal level aimed at improving access to addiction care, including medication assisted treatment. Workshop presenters will also discuss potential future federal developments related to substance use disorder treatment, the future of medication assisted treatment in the new health reform environment, delivery system reforms, and opportunities available for improving federal policy moving forward.

**E4 Benzodiazepines and Opioids: An Update**

Yngvild Olsen, MD, Institutes for Behavior Resources, Inc, Baltimore, MD
Christopher Welsh, MD, University of Maryland School of Medicine, Baltimore, MD
Anika Alvanzo, MD, Johns Hopkins University School of Medicine, Baltimore, MD

There is growing epidemiologic data on overdose fatalities associated with opioids and benzodiazepines. Clinicians caring for patients taking methadone or buprenorphine often struggle with what to do when patients also use illicit or prescribed benzodiazepines. Using a case based format, this workshop will review contextual data and survey results for how opioid treatment programs deal with concurrent benzodiazepine use. Presenters will focus on recent clinical guidelines, practical ways to reduce safety risks, including the use of technological tools, and discuss broader policy initiatives such as the Food and Drug Administration petition for black box warnings on all prescription opioids and benzodiazepines.

**E5 Opportunities for Using Addiction Medications: NYS Recipe for Success**

Robert A. Kent, Esq., New York State Office of Alcoholism and Substance Abuse Services (OASAS), Albany, NY
Charles W. Morgan, MD, New York State Office of Alcoholism and Substance Abuse Services (OASAS), Rochester, NY
Belinda M. Greenfield, PhD, New York State Office of Alcoholism and Substance Abuse Services (OASAS), New York, NY

Although New York State (NYS) has a robust Opioid Treatment Program (OTP) system that has a solid historical foundation and serves the largest number of patients nationally (over 38,124 patients daily), the state continues to struggle with addiction medication adoption and access. NYS leadership have developed strategies to improve addiction medication access and concomitantly increase the substance use disorder (SUD) field capacity to integrate pharmacological agents alongside counseling services. This workshop will delineate these strategies, presenting both challenges and solutions to improve SUD treatment quality. The workshop’s goal is to help states with their own medication assisted treatment adoption, access and capacity gaps by considering NYS’ action plan.
F3 Recognizing and Addressing Problem Gambling in Patients Receiving Medication Assisted Treatment

Chris Welsh, MD, University of Maryland School of Medicine, Baltimore, MD
Lori Rugle, PhD, Maryland Center of Excellence on Problem Gambling, Columbia, MD

This workshop will provide an overview on the topic of problematic/pathological gambling, which may be present in greater than 50% of patients in methadone treatment. It will cover DSM/ICD diagnostic criteria, epidemiology, comorbidities and possible treatments. It will also describe common screening instruments, educational materials, and brief interventions to address gambling problems. It will show how to focus on gambling behaviors in the context of recovery from opioid addiction. The workshop will utilize presentation of factual information as well as interactive case examples and role-play of screening and interventions.

F4 The Challenges of Treating Chronic Pain and an Opioid Use Disorder in Medication Assisted Treatment

Mark L. Kraus, MD, Connecticut Counseling Centers, Inc., Danbury, CT
Joseph G. Conrad, PsyD, Connecticut Counseling Centers, Inc., Danbury, CT

This workshop will provide an in depth look at a patient population that we see in our Medication Assisted Treatment (MAT) Programs and Primary Care Settings, i.e., those patients who struggle with a primary opioid use disorder and are concomitantly being treated for chronic pain. The workshop content will be focusing on issues inclusive of epidemiology, triage, and intervention in regard to the physician’s and clinician’s role in managing these patients to achieve the best possible therapeutic and medical outcomes. Specific focus will also be given to addressing prescription practices and discussing an “Integrative Model of Care.”
CLOSING PLENARY SESSION
11:30 a.m.–12:45 p.m.

The Federal Response to the Opioid Epidemic

MODERATOR:
Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc. (AATOD), New York, NY

KEYNOTE ADDRESS:
Michael Botticelli, MEd, Director of Office of National Drug Control Policy (ONDCP), Washington, DC
Loretta Lynch, JD, Attorney General, United States Department of Justice, Washington, DC (Invited)

The Closing Plenary Session will feature two major keynote addresses that cannot be missed for advocates, stakeholders, providers, and patients. As Director of National Drug Control Policy, Mr. Botticelli leads the Obama Administration’s drug policy efforts, which are based on a balanced public health and public safety approach. In response to the national opioid epidemic, Mr. Botticelli has coordinated actions across the Federal government to reduce prescription drug abuse, heroin use, and related overdoses. These include supporting community-based prevention efforts; expanding use of the naloxone by law enforcement; and increasing access to medication assisted treatment. Director Botticelli will discuss White House policies on National Drug Control. As US Attorney General, Loretta Lynch has pledged to help fight opioid abuse. During this session, Attorney General Lynch will provide insight on current efforts by the Criminal Justice System to save lives, reduce recidivism, and foster recovery for people with substance use disorder. Make sure that your plans make it possible for you to be at this important event!

1:00 p.m.–3:30 p.m. (subject to change)

Visit the Hospitality Table on-site for more information and to sign up for the tours.

Glenwood Life Counseling Center

2016 marks 45 years of continuous service by Glenwood Life Counseling Center to the citizens of Baltimore. In 1971, Glenwood Life Counseling Center opened its doors as a small Opioid Treatment Program with the vision that “patients can embrace recovery and live healthy, drug free and productive lives.” To this day the much louder, prouder and bigger Glenwood Life Counseling Center continues our mission: “To deliver quality, medication assisted treatment to opiate addicted adults in the least restrictive, most respectful manner possible.”

We are a CARF certified, private nonprofit providing community based comprehensive outpatient substance use disorders treatment.

We pride ourselves on the many paths to recovery that we offer, including medication assisted treatment individual and group therapy, counseling, case management, interdisciplinary treatment team, IOP, and Health Home provided by our professional staff, as well as many peer driven services such as Peer Case Management, our recovery garden, the praise dance team, food bank, babysitting, our lending library, and community outreach.

Man Alive

The first medication assisted treatment program in Maryland and second oldest in the country, Man Alive, Inc. has grown considerably since its inception in 1967. Man Alive provides a comprehensive, evidence-based, behavioral model of services, which are delivered by compassionate, highly skilled professionals and consumers.

Artists in the field of writing, theatre, dance, music, photography and Qigong enrich the consumers’ lives by volunteering their time and expertise on site. Our philosophical model is deeply rooted in eliminating stigma by providing progressive and innovative treatment.

Institutes for Behavior Resources, Inc.

REACH Health Services has been providing medication assisted treatment services since 1991, first from a mobile unit that traveled to four locations in the city, to our current, fixed site facility in the Old Goucher neighborhood of Baltimore City. We are the clinical services program within the Institutes for Behavior Resources and provide community based comprehensive outpatient substance use disorders treatment including medication assisted treatment, outpatient treatment, intensive outpatient treatment, family planning, peer recovery support, anti-stigma education and advocacy, and health home care management services to residents of Baltimore City and the surrounding areas.

Additional service provision is enhanced through a close collaboration with local health care providers including somatic care, psychiatric rehabilitation facilities, homeless outreach services, food closets, shelters, etc. REACH is located in a neighborhood that offers a wide variety of mental health and somatic health care services. REACH is a CARF accredited program and has been since 2006.

The staff at REACH believe that addiction is a chronic disease, that recovery from the disease is possible; and that the treatment of addictive disorders does not happen in a vacuum and not only within the walls of the program. We strongly believe that recovery is self-directed and empowering, involves a personal recognition of the need for change and transformation, is holistic, has cultural dimensions, exists on a continuum of health and wellness, involves a process of healing and self-redefinition, involves transcending shame and stigma, is supported by allies, family and peers, and involves re-building a life in the community.
“Charm City” Baltimore is the site of the 2016 AATOD Conference, and on behalf of the Hospitality Committee, we are thrilled to be sharing our great and sometimes quirky city with you.

The conference will be held at the Baltimore Marriott Waterfront, situated in Harbor East, a “city within a city” that has become part of the skyline over the last 15 years. It is full of excellent restaurants and boutiques and the views of Baltimore’s redeveloped waterfront are superb.

The hotel is a short walk from the world-famous Inner Harbor, with shops and restaurants along a brick promenade that rings the Inner Harbor. The promenade serves as a seven-mile pathway connecting one edge of the harbor rim to the other—from historic Fort McHenry, site of the 1814 battle that inspired Francis Scott Key’s writing of “The Star-Spangled Banner,” to Canton, the exciting southeast Baltimore neighborhood that has seen tremendous population growth over the last three decades.

Baltimore is also known as “the City of Neighborhoods” . . . hundreds and hundreds of them with unique character, architecture, and foods! We are home to some of the earliest National Register historic neighborhoods in the nation, including Federal Hill, Mount Vernon Place and Fells Point. Speaking of which, there are very few places on earth more entertaining, creative and zany than Fells Point on Halloween, due in no small measure to the Maryland Institute of Art (MICA) students and the large artistic community in Baltimore. Bring a costume (you’ll fit right in) or at least a camera; no one back home will believe it otherwise!

Baltimore has more public monuments than any other city per capita in the country and is home to many great museums: The Walters Art Gallery, the Baltimore Museum of Art (featuring a world-famous collection of Matisse), the B&O Railroad Museum, and Great Blacks in Wax. Just a short stroll from the Baltimore Marriott Waterfront are the Star-Spangled Banner House, where Mary Pickersgill sewed the flag that inspired Key to write our national anthem; the Reginald F. Lewis Museum of Maryland African-American History and Culture; the Jewish Museum of Maryland and one of the nation’s oldest synagogues; and the Baltimore Civil War Museum at President Street Station, which explores the city’s status during the war and its connection to the Underground Railroad. Most of these wonderful amenities are accessible by an MTA bus or Baltimore’s free Charm City circulator.

We look forward to seeing you in October. Stop by the Hospitality booth and we will “point you in the right direction!”

Sincerely,
Lillian M. Donnard, LCSW-C
AATOD Hospitality Chair
HOTEL INFORMATION

BALTIMORE MARRIOTT WATERFRONT
700 Aliceanna Street
Baltimore, Maryland 21202
Tel: +1 410-385-3000
www.marriott.com/hotels/travel/bwiwf-baltimore-marriott-waterfront

Sleeping rooms have been reserved for attendees at a conference rate of $199 single/double occupancy. This reduced rate is available until Thursday, October 6, 2016, subject to availability. Reservation requests received after the cut-off date of Thursday, October 6, 2016 will be based on availability at the hotel’s prevailing rates.

To reserve a room at the group rate, please click on the link in the Conference section of the AATOD website or contact the hotel directly by calling their reservation line at 410-385-3000. Please be sure to reference the American Association for the Treatment of Opioid Dependence or AATOD Conference.

CONFERENCE CONTACTS
Talley Management Group, Inc.
Alexandra Springer, CMP–Meetings & Exhibits Manager
19 Mantua Road
Mount Royal, New Jersey 08061
Phone: 856-423-3091
Fax: 856-423-3420
E-mail: aatod@talley.com
Website: www.aatod.org

Exhibit Sales
Teresa Matozzo, Sales Associate
tmatozzo@talley.com

CONTINUING EDUCATION CREDITS
AATOD is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC), Provider #000218.

Application to award Continuing Education Credits will be submitted for the following specialties:
- Counseling
- Nursing
- Physicians
- Social Workers
REGISTRATION & FEES

Saving Lives: Access to Improved Health & Recovery

Registration for the American Association for the Treatment of Opioid Dependence, Inc. (AATOD) conference can be done on-line by visiting the AATOD website at www.aatod.org or by completing the registration form on the inside back cover and faxing it to 856-423-3420 or by mailing it to:
AATOD 2016 Conference Registration
c/o Talley Management Group, Inc.
19 Mantua Road
Mt. Royal, NJ 08061

If faxing your registration, DO NOT mail the original form; doing so may result in duplicate charges to your credit card! Should you have any questions regarding conference registration please call 856-423-3091.

You may register online at www.aatod.org by clicking on the ONLINE REGISTRATION LINK or by completing the Registration Form and mailing or faxing it to the address provided.

You may register two or more from an Agency through the AATOD website.

**PRE-REGISTRATION ENDS SEPTEMBER 30, 2016**

<table>
<thead>
<tr>
<th>Full Conference Registration *</th>
<th>1 person from an agency</th>
<th>2 or more from an agency, each</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard Registration:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>February 1, 2016–September 30, 2016</td>
<td>$ 510.00</td>
<td>$ 485.00</td>
</tr>
<tr>
<td><strong>On-Site Rates:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 1, 2016–November 2, 2016</td>
<td>$ 595.00</td>
<td>No Group Discounts Available</td>
</tr>
</tbody>
</table>

*Includes: Admission to Pre-Conference Sessions (excluding Clinicians Course), Welcome Reception, Plenary Sessions, Workshops, continental breakfasts, and Awards Banquet.

Splitting of conference fees is not permitted. Only one discount per conference participant is allowed, including the presenter’s discount.

**Group Discounts do not apply for the following categories:**

- **Single Day Registration**: $260.00 (Does NOT include Welcome Reception or Awards Banquet)
- **Clinicians Course**: $235.00
- **Additional Awards Banquet Tickets**: $85.00
- **Additional Welcome Reception Tickets**: $40.00

*Information included in this publication is subject to change.

**CME/CEH FEES**

These fees are not included in full conference registration fee

- Physicians/Physician Assistants/Pharmacists: $50.00
- Nurses/Social Workers/Psychologists: $40.00
- Counselors: $30.00

**CONFERENCE RECORDINGS**

AATOD has contracted to have all conference sessions recorded. Order the recordings in advance and save. You can purchase all pre-conference sessions or all workshop sessions in advance for $125 each or save even more and buy both sets for $200.

Participation in this conference assumes knowledge and authorization of photography, audio and/or video recording of portions of this conference. If you do not want to be photographed or videotaped, please notify the individuals taking photographs, recording and/or videoing the event.

**SPECIAL NEEDS**

The American Association for the Treatment of Opioid Dependence, Inc. wishes to take steps to ensure that no disabled person is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you require any auxiliary aids or services identified in the Americans with Disabilities Act, please indicate so during the registration process.
2016 CONFERENCE
OCTOBER 29–NOVEMBER 2, 2016

Please register online at www.aatod.org and click on the ONLINE REGISTRATION link or complete the registration form. Use one form for each registrant. Photo-copies of the form are acceptable.

You may now register two or more from an Agency through the AATOD website.

CONTACT INFORMATION: Please print. Bold fields will print on badge.

**First (Given) Name** ____________________________________________________________________
**Middle Name** ______________________________________________________________________
**Last (Family) Name** ___________________________________________________________________

---

**Name on Badge** ______________________________________________________________________
**Affiliation (Employer)** ______________________________________________________________________
**Position/Title** ______________________________________________________________________
**Business Address** ______________________________________________________________________
**City** ______________________________________________________________________
**State/Province** ______________________________________________________________________
**Country** ______________________________________________________________________
**Zip Code** ______________________________________________________________________
**Business Telephone** ______________________________________________________________________
**Fax Number** ______________________________________________________________________
**E-Mail Address** ______________________________________________________________________

---

Please check only the professional designation that applies:

- [ ] Administrative/Management
- [ ] Clinical/Medical
- [ ] Counseling
- [ ] Funding/Evaluation
- [ ] Policy
- [ ] Research
- [ ] Other (Please Specify)
- [ ] Other

**Full Conference Registration:**
Includes Welcome Reception and Awards Banquet (check all that apply)

<table>
<thead>
<tr>
<th>2/1/2016–9/30/2016</th>
<th>On-Site</th>
<th>Fee enclosed</th>
</tr>
</thead>
<tbody>
<tr>
<td>One person from an agency</td>
<td>$510</td>
<td>$595</td>
</tr>
<tr>
<td>Two or more from an agency, each</td>
<td>$485</td>
<td>$595</td>
</tr>
<tr>
<td>Single Day (specify day below)</td>
<td>$260</td>
<td>$260</td>
</tr>
<tr>
<td>Saturday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday (does not include Welcome Reception)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday (Does not include Awards Banquet)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes, I will be attending the Welcome Reception</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No, I will not attend the Welcome Reception</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes, I will be attending the Awards Banquet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No, I will not attend the Awards Banquet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinicians Course</td>
<td>$235</td>
<td>$__________</td>
</tr>
<tr>
<td>Additional Awards Banquet tickets</td>
<td>$85</td>
<td>$__________</td>
</tr>
<tr>
<td>Additional Welcome Reception tickets</td>
<td>$40</td>
<td>$__________</td>
</tr>
</tbody>
</table>

**CME/CEH Fees (Not included in conference registration fee)**
Please indicate the type of continuing education units you intend to seek:

- [ ] Physicians
- [ ] Physician Assistants
- [ ] Pharmacists $50 $__________
- [ ] Nurses
- [ ] Social Workers
- [ ] Psychologists $40 $__________

Social Worker License #____________________ State of Licensure ________

- [ ] Counselors $30 $__________

**SESSION RECORDINGS (MP3)**

Pre-conference Session Recordings (advance order price $125) $__________
Regular Conference Session Recordings (advance order price $125) $__________
All Conference Session Recordings (advance order price $200) $__________

**TOTAL FEES** $__________

---

PAYMENT INFORMATION:

- [ ] Enclosed is payment by CHECK payable to the American Association for the Treatment of Opioid Dependence, Inc.

To assure prompt processing of your registration, please be sure to remit your check in U.S. dollars and issued by a U.S. correspondent bank. Please check with your local bank before processing payment. Each registrant is responsible for any and all bank charges. A $50.00 processing fee will be charged for checks returned unpaid.

- [ ] I wish to pay my fees by CREDIT CARD

Please note this charge will appear on your statement as “AATOD Conference Registration”

- [ ] Visa  [ ] MasterCard  [ ] American Express

Please provide card number and expiration date below.

**Total fees to be charged** $__________

**Cardholder’s Signature** ______________________________________________________________________

Registrations paid by credit card may be faxed to 856-423-3420. Please keep a copy of your fax confirmation for your record. If faxing, DO NOT mail the original form; doing so may result in duplicate charges to your credit card! AATOD reserves the right to charge the correct amount if different from the total above.

**AATOD does not accept purchase orders as a form of payment.**

---

**CANCELLATION POLICY**
If you must cancel your registration, the American Association for the Treatment of Opioid Dependence, Inc. Registration Department must receive all requests in writing no later than September 30, 2016. All fees paid will be returned less a $50.00 processing fee. **There will be no refunds after the September 30th deadline.**

**REPLACEMENT POLICY**
Replacements will be processed when requests are received in writing prior to September 30, 2016 at no charge. A fee of $50 per registrant will apply as of October 1, 2016.

Participation in this conference assumes knowledge and authorization of audio and/or video recording of portions of this conference.

Registration will be confirmed via the email address provided within two weeks of receipt of payment. If you do not receive confirmation by that time, please call 856-423-3091.

---

**CREDIT CARD INFORMATION**

[ ] Visa  [ ] MasterCard  [ ] American Express

**ACCOUNT NUMBER** ______________________________________________________________________

**EXPIRATION DATE (mm/yy)** ______________________________________________________________________